维普期刊资源整合服务平台（V6.5）

159篇 您的检索式：作者名="Wilson WH"

选中清除导出查看参考文献查看引证文献引用追踪共8页首页上一页第1页下一页末页 /8 跳转

	题名	作者	年代	出处	被引量
1	AngioimmunoblasticT cell lymphoma: pathobiological insights and clinicalimplications显示文摘	Dunleavy K Wilson WH Jaffe ES	2007	Curr Opin Hematol2007，14，4：	1
2	Phase Ⅱ study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers显示文摘	Wilson WH Dunleavy K Pittaluga S	2008	J Clin Oncol2008，26，16：	1
3	The role of rituximab and chemotherapy in aggressive B-cell lymphoma:a preliminary report of dose-adjusted EPOCH-R显示文摘	Wilson WH Gutierrez M O′Connor P	2002	Semin Oncol2002，29，12：	1
4	Angioimmunoblastic T- cell lymphoma: Immune modulation as a therapeutic strategy 显示文摘	Dunleavy K Wilson WH	2007	Leuk Lymphoma2007，48，3：	1
5	A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype显示文摘	Wilson WH Jung SH Porcu P	2012	Haematologica2012，97，5：	1
6	Navitoclax,a targeted high-affinity inhibitor of BCL-2,in lymphoid malignancies:A phase Ⅰ dose-escalation study of safety,pharmacokinetics,pharmacodynamics,and antitumour activity显示文摘	Wilson WH O'Connor OA Czuczman MS		0，，12：	1
7	Lymphomatoid granulomatosis 显示文摘	Hoschewski M Wilson WH	2012	Cancer J2012，18，5：	1
8	Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha-2b显示文摘	Wilson WH Kingma DW Raffeld M	1996	Blood1996，87，11：	1
9	The BCL-2 hiomarker in the era of molecular diagnosis of diffuse large B-cell lymphoma显示文摘	Dunleavy K Staudt LM Wilson WH		0，，06：	1
10	The year in heart failure显示文摘	Wilson Tang WH Francis GS	2007	J AM Coll Cardiol2007，50，：	1
11	Eadication of B-lineage cels and regresion of lymphoma in a patient treated with autolognus T eelsgeneti- ealyenginered to recognize CD19 显示文摘	Kochenderfer JN Wilson WH Rosenberg SA	2010	Blood2010，116，20：	1
12	Relationship of p53, bcl-2 and proliferation to clinical drug resistance innon-Hodgkin slymphomas显示文摘	Wilson WH Teruya Feldstein j Fest T	1997	Blood1997，89，2：	1
13	Eradication of B- lineage cells and regression of lymphoma in a patient treated with autologous T ceils genetically engineered to recognize CD19 显示文摘	Kochenderfer JN Wilson WH Janik JE	2010	Blood2010，116，20：	1
14	The BCL-2 biomarker in the era of molecular diagnosis of diffuse large B-cell lymphoma显示文摘	Dunleavy K Staudt LM Wilson WH	2007	Leuk Lymphoma2007，48，6：	1
15	EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma显示文摘	Wilson WH Bryant G Bates S	1993	J Clin Oncol1993，11，：	1
16	Eradication of B- lin-58, cage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 显示文摘	Kochenderfer JN Wilson WH Janik JE	2010	Blood2010，116，20：	1
17	Phase Ⅰtrial of recombinant immunotoxin anti-Tac(Fv)-PE38(BL22) toward fresh malignant cells from patients with B-cell leukemias显示文摘	Kreitman RJ Wilson WH White JD	2000	Clin Cancer Res2000，6，4：	1
18	Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure显示文摘	Wilson Tang WH Girod JP Lee MJ	2003	Circulation2003，108，：	1
19	Relationship of p53,bcl-2 and proliferation to clinical drug resistance in non-Hodgkin′slymphomas显示文摘	Wilson WH Teruya-Feldstein J Fest T	1997	Blood1997，89，：	1
20	Controlled of multidrug resistance inlymphoma srefractory to EPOCE chemotherapy 显示文摘	Wilson WH Bates SE Fojo A	1995	J Clin Once1995，13，：	1

返回顶部每页显示：

共8页首页上一页第1页下一页末页 /8 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示